Progress of chimeric antigen receptor T-cell in treatment of multiple myeloma
10.3760/cma.j.cn115356-20230102-00001
- VernacularTitle:嵌合抗原受体T细胞治疗多发性骨髓瘤研究进展
- Author:
Yuntong LIU
1
;
Gang AN
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Multiple myeloma;
Chimeric antigen receptor T-cell;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2023;32(5):270-273
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) immunotherapy targeting B-cell maturation antigen (BCMA) has shown significant efficacy in relapsed/refractory multiple myeloma. With the rapid development of CAR-T therapies, CAR-T therapies targeting BCMA continue to be optimized, and new products such as new targets, dual-targets and universal CAR-T are arriving successively. Data from several relevant clinical studies were updated at the 64th American Society of Hematology Annual Meeting.
